Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THR092
MIFTS: 67

Thrombophilia Due to Thrombin Defect

Categories: Genetic diseases, Blood diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thrombophilia Due to Thrombin Defect

About this section

MalaCards integrated aliases for Thrombophilia Due to Thrombin Defect:

Name: Thrombophilia Due to Thrombin Defect 57 75 13
Venous Thrombosis 57 75 29 55 73
Venous Thromboembolism 57 75 3 73
Thromboembolism 57 55 6 73
Venous Thromboembolism, Susceptibility to 57 6
Venous Thrombosis, Protection Against 57 6
Thrombophilia Due to Factor 2 Defect 57 75
Venous Thrombosis, Susceptibility to 29 6
Thph1 57 75
Thromboembolism, Susceptibility to 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
onset in childhood


HPO:

32
thrombophilia due to thrombin defect:
Inheritance autosomal dominant inheritance
Onset and clinical course childhood onset


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Thrombophilia Due to Thrombin Defect

About this section
OMIM : 57 Thrombophilia is a multifactorial disorder of inappropriate clot formation resulting from an interaction of genetic, acquired, and circumstantial predisposing factors. Venous thromboembolism most commonly manifests as deep vein thrombosis, which may progress to pulmonary embolism if the clot dislodges and travels to the lung. Other manifestations include thromboses of the cerebral or visceral veins and recurrent pregnancy loss (summary by Seligsohn and Lubetsky, 2001 and Varga and Kujovich, 2012). (188050)

MalaCards based summary : Thrombophilia Due to Thrombin Defect, also known as venous thrombosis, is related to may-thurner syndrome and post-thrombotic syndrome. An important gene associated with Thrombophilia Due to Thrombin Defect is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Dalteparin and Enoxaparin have been mentioned in the context of this disorder. Affiliated tissues include liver, eye and lung, and related phenotypes are thromboembolism and pulmonary embolism

UniProtKB/Swiss-Prot : 75 Thrombophilia due to thrombin defect: A multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.

CDC : 3 Venous thromboembolism (VTE), also known as blood clots, is an underdiagnosed and serious, but preventable medical condition. It is important to know about VTE because it can happen to anybody at any age and cause serious illness, disability, and in some cases, death. The good news is that VTE can be prevented and treated if discovered early.

Sources

Related Diseases for Thrombophilia Due to Thrombin Defect

About this section

Diseases in the Thrombophilia family:

Thrombophilia Due to Thrombin Defect Thrombophilia Due to Activated Protein C Resistance
Thrombophilia, Familial, Due to Decreased Release of Tissue Plasminogen Activator Thrombophilia Due to Thrombomodulin Defect
Prothrombin-Related Thrombophilia

Diseases related to Thrombophilia Due to Thrombin Defect via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 may-thurner syndrome 33.2 APOH F5
2 post-thrombotic syndrome 31.8 F2 F5 F8 SERPINC1 SERPINE1
3 protein s deficiency 31.8 APOH F2 F3 F5 MTHFR SERPINC1
4 homocysteinemia 31.7 CBS F2 F5 MTHFR SERPINC1
5 antithrombin iii deficiency 31.6 APOH F10 F2 F5 MTHFR SERPINC1
6 portal vein thrombosis 31.5 APOH F2 F5 MTHFR SERPINC1 SERPINE1
7 protein c deficiency 31.0 F2 F5 MTHFR PROC SERPINC1 THBD
8 afibrinogenemia, congenital 30.9 F2 F3 F8 VWF
9 pulmonary embolism 29.8 APOH F10 F2 F3 F5 MTHFR
10 chronic thromboembolic pulmonary hypertension 12.4
11 pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis 12.3
12 thrombophilia, x-linked, due to factor ix defect 11.3
13 factor v leiden thrombophilia 11.3
14 prothrombin-related thrombophilia 11.3
15 thrombophilia due to protein c deficiency, autosomal dominant 11.1
16 thrombophilia due to protein c deficiency, autosomal recessive 11.1
17 thrombophilia due to protein s deficiency, autosomal dominant 11.1
18 thrombophilia due to thrombomodulin defect 11.1
19 portal hypertension, noncirrhotic 11.1
20 mesenteric vascular occlusion 10.9 F2 MTHFR
21 paracetamol poisoning 10.9 F2 F5
22 cerebral falx meningioma 10.9 F2 F3
23 acanthamoeba keratitis 10.8 APOH F5
24 ischemic neuropathy 10.8 F2 MTHFR
25 alpha-2-plasmin inhibitor deficiency 10.8 F2 SERPINC1
26 hemoglobin e disease 10.8 F2 F5
27 splenic infarction 10.7 APOH F2
28 pregnancy loss, recurrent 1 10.7 APOH F5
29 porencephaly 10.7 F2 F5 MTHFR
30 arteritic anterior ischemic optic neuropathy 10.7 F2 F5 MTHFR
31 breast reconstruction 10.7 APOH F8
32 cerebral palsy 10.6 F2 F5 MTHFR
33 intestinal impaction 10.6 F2 F3 SERPINC1
34 giant hemangioma 10.6 F2 F3 SERPINC1
35 factor v and factor viii, combined deficiency of, 2 10.6 F5 F8
36 papilledema 10.6 APOH F2
37 femoral neuropathy 10.6 F2 F3
38 hemorrhagic fever 10.6 F2 F3 SERPINC1
39 hepatitis a 10.6 F2 F3 SERPINC1
40 scott syndrome 10.6 F10 F2 F5
41 inferior vena cava interruption 10.6 F5 MTHFR SERPINE1
42 thrombocytosis 10.6 F2 F3 SERPINC1
43 hantavirus pulmonary syndrome 10.5 F2 F3
44 amaurosis fugax 10.5 F5 MTHFR SERPINE1
45 alcohol-related birth defect 10.5 F2 F3 F8
46 vitamin k deficiency hemorrhagic disease 10.5 F2 F8
47 subendocardial myocardial infarction 10.5 F2 SERPINC1 SERPINE1
48 anterior cranial fossa meningioma 10.5 F2 F3
49 heparin-induced thrombocytopenia 10.5 F10 F3 SERPINC1
50 plasminogen activator inhibitor-1 deficiency 10.5 PLAT SERPINE1

Comorbidity relations with Thrombophilia Due to Thrombin Defect via Phenotypic Disease Network (PDN): (show all 15)


Active Peptic Ulcer Disease Acute Cystitis
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Femoral Vein Thrombophlebitis Heart Disease
Hypertension, Essential Hypothyroidism
Ischemic Heart Disease Osteoporosis
Peripheral Vascular Disease Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Thrombophilia Due to Thrombin Defect:



Diseases related to Thrombophilia Due to Thrombin Defect
Sources

Symptoms & Phenotypes for Thrombophilia Due to Thrombin Defect

About this section

Symptoms via clinical synopsis from OMIM:

57
Cardiovascular Vascular:
thrombosis, recurrent
deep vein thrombosis

Neurologic Central Nervous System:
cerebral thrombosis

Respiratory Lung:
pulmonary embolism


Clinical features from OMIM:

188050

Human phenotypes related to Thrombophilia Due to Thrombin Defect:

32
# Description HPO Frequency HPO Source Accession
1 thromboembolism 32 HP:0001907
2 pulmonary embolism 32 HP:0002204
3 deep venous thrombosis 32 HP:0002625
4 recurrent thrombophlebitis 32 HP:0004419
5 cerebral venous thrombosis 32 HP:0005305

MGI Mouse Phenotypes related to Thrombophilia Due to Thrombin Defect:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 PROC F5 APOH F10 F8 F13A1
2 cardiovascular system MP:0005385 10.25 PLOD1 F5 F10 F13A1 F2 PLAT
3 hematopoietic system MP:0005397 10.14 F3 F8 F13A1 F2 PLAT THBD
4 mortality/aging MP:0010768 10.09 PLOD1 PROC F5 APOH F10 F8
5 immune system MP:0005387 10.06 F3 F8 HABP2 F2 PLAT THBD
6 integument MP:0010771 9.86 PLOD1 F3 F5 MTHFR F2 PLAT
7 reproductive system MP:0005389 9.56 F10 F8 F13A1 MTHFR F2 PLAT
8 respiratory system MP:0005388 9.17 F3 F13A1 F2 PLAT SERPINE1 THBD
Sources

Drugs & Therapeutics for Thrombophilia Due to Thrombin Defect

About this section

Drugs for Thrombophilia Due to Thrombin Defect (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 586)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6
2
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772
3
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772 46507594
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
5 Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9041-08-1
6
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 6691 54678486
7
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 366789-02-8
8
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
9
Tranylcypromine Approved, Investigational Phase 4,Phase 3 155-09-9 441233
10
Estradiol Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-28-2 5757
11 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Not Applicable 979-32-8
12
Norethindrone Approved Phase 4 68-22-4 6230
13
Polyestradiol phosphate Approved Phase 4,Not Applicable 28014-46-2
14 fluindione Approved, Investigational Phase 4 957-56-2
15
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
16
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 50-78-2 2244
17
Clopidogrel Approved Phase 4,Phase 3 120202-66-6, 113665-84-2 60606
18
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
19
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
21
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
22
Tinzaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6, 9041-08-1 25244225
23 Fondaparinux Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 104993-28-4
24
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 137-58-6 3676
25
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
26
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 71273 175805
27
Apixaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 503612-47-3 10182969
28
Acenocoumarol Approved, Investigational Phase 4,Phase 3,Not Applicable 152-72-7 9052 54676537
29
Dipyridamole Approved Phase 4,Phase 3 58-32-2 3108
30
Cisplatin Approved Phase 4,Phase 3,Phase 2 15663-27-1 84093 441203 2767
31
Ethiodized oil Approved, Investigational Phase 4,Not Applicable 8008-53-5
32
Polidocanol Approved Phase 4,Not Applicable 9002-92-0
33
Pancrelipase Approved, Investigational Phase 4,Phase 3 53608-75-6
34
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
35
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
36 Edoxaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 480449-70-5
37
Conivaptan Approved, Investigational Phase 4 210101-16-9 151171
38
Ibuprofen Approved Phase 4 15687-27-1 3672
39
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
40
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3 69-72-7 338
41
Anagrelide Approved Phase 4 68475-42-3 2182
42
Hydroxyurea Approved Phase 4,Phase 3,Phase 2 127-07-1 3657
43
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
44
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
45
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
46
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
47
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
48
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
49
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
50
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054

Interventional clinical trials:

(show top 50) (show all 1503)
# Name Status NCT ID Phase Drugs
1 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis Unknown status NCT01252420 Phase 4 Enoxaparin
2 Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis Unknown status NCT00450645 Phase 4 low molecular weight heparin
3 Rosuvastatin for Preventing Deep Vein Thrombosis Unknown status NCT01021488 Phase 4 Rosuvastatin 20mg/d for 14days;enoxaparin only
4 Safety and Efficacy Study of OmniWave Endovascular System to Treat Deep Vein Thrombosis Unknown status NCT00640731 Phase 4
5 The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
6 Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Unknown status NCT01063426 Phase 4 High dose Atorvastatin+enoxaparin;Enoxaparin
7 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
8 Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
9 Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation Unknown status NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
10 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
11 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
12 The Use of Prostaglandin E1 in Head and Neck Microsurgery Unknown status NCT00733434 Phase 4 Prostaglandin E1
13 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
14 Retinal Sensitivity in BRVO After Anti-VEGF Therapy Unknown status NCT02527733 Phase 4 Ranibizumab;Ranibizumab and laser
15 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
16 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
17 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
18 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
19 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
20 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
21 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
22 Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures Unknown status NCT02580227 Phase 4 Tranexamic Acid
23 Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study Completed NCT02581176 Phase 4 Apixaban
24 Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants Completed NCT00623987 Phase 4 warfarin accordingly INR value
25 Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants Completed NCT00438230 Phase 4 Warfarin
26 Treatment of Upper Extremity Deep-Vein Thrombosis Completed NCT00245856 Phase 4 Dalteparin sodium injection;Warfarin
27 Cystic Fibrosis and Totally Implantable Vascular Access Devices Completed NCT00244270 Phase 4
28 Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis Completed NCT00277394 Phase 4 innohep®;Heparin
29 Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis Completed NCT00689520 Phase 4 tinzaparin;acenocoumarol
30 Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study) Completed NCT00203580 Phase 4 Tinzaparin sodium
31 Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
32 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
33 Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin Completed NCT01354704 Phase 4 Enoxaparin
34 Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin Completed NCT00203658 Phase 4 Tinzaparin sodium
35 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
36 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Completed NCT00365950 Phase 4 Duration of anticoagulation;Warfarin duration
37 Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT Completed NCT00585182 Phase 4 Enoxaparin 0.5 mg/kg once daily
38 Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty Completed NCT02379663 Phase 4 Rivaroxaban;Enoxaparin
39 Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2) Completed NCT01708850 Phase 4 Rivaroxaban
40 Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty Completed NCT02102828 Phase 4 Aspirin only
41 The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients Completed NCT00351663 Phase 4 Enoxaparine
42 Enoxaparin in Acute Venous Thromboembolic Disease Completed NCT00265993 Phase 4 enoxaparin
43 PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption Completed NCT00457158 Phase 4
44 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
45 Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Completed NCT01989845 Phase 4 Rivaroxaban
46 The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial Completed NCT00187408 Phase 4 Low Molecular Weight Heparin (dalteparin)
47 D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Completed NCT00264277 Phase 4 Vitamin K antagonist (Coumarin anticoagulants)
48 Rivaroxaban for Antiphospholipid Antibody Syndrome Completed NCT02116036 Phase 4 Rivaroxaban
49 The Use of Low Molecular Weight Heparin in Traumatic Brain Injury Completed NCT00170378 Phase 4 Enoxaparin
50 The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis Completed NCT02458729 Phase 4 Tranexamic Acid 5%,5ml/amp (intraoperative);Tranexamic Acid 5%,5ml/amp (3 hours after operation);0.9% Normal Saline (intraoperative);0.9% Normal Saline (3 hours after operation);rivaroxaban (10mg)

Search NIH Clinical Center for Thrombophilia Due to Thrombin Defect

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Thrombophilia Due to Thrombin Defect

About this section

Genetic tests related to Thrombophilia Due to Thrombin Defect:

# Genetic test Affiliating Genes
1 Venous Thrombosis 29
2 Venous Thrombosis, Susceptibility to 29
Sources

Anatomical Context for Thrombophilia Due to Thrombin Defect

About this section

MalaCards organs/tissues related to Thrombophilia Due to Thrombin Defect:

41
Liver, Eye, Lung, Brain, Testes, Kidney, Heart
Sources

Publications for Thrombophilia Due to Thrombin Defect

About this section

Articles related to Thrombophilia Due to Thrombin Defect:

(show top 50) (show all 1547)
# Title Authors Year
1
Spontaneous intracranial hypotension complicated by cerebral venous thrombosis. ( 29955241 )
2018
2
Late diagnosis of homocystinuria in an adult after extensive cerebral venous thrombosis. ( 29175875 )
2018
3
Adalimumab-based treatment versus DMARDs for venous thrombosis in BehAset syndrome. A retrospective study of 70 patients with vascular involvement. ( 29676522 )
2018
4
Prevention of recurrent venous thrombosis and post-thrombotic syndrome. ( 29795059 )
2018
5
Congenital Thrombophilia in Patients With Superior Mesenteric Venous Thrombosis or Portal Vein Thrombosis. ( 29747524 )
2018
6
May-Thurner Syndrome Presenting as Acute Unexplained Deep Venous Thrombosis. ( 29793013 )
2018
7
Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. ( 29402471 )
2018
8
Coexistent Ipsilateral Internal Carotid Artery Occlusion and Cerebral Venous Thrombosis in Hepatitis C. ( 29349091 )
2018
9
Serum neuron specific enolase may be a marker to predict the severity and outcome of cerebral venous thrombosis. ( 29128928 )
2018
10
Recurrent Iliofemoral Venous Thrombosis in the Setting of May-Thurner Syndrome as the Presenting Symptom of Behcet's Disease. ( 29481922 )
2018
11
An assessment of deep venous thrombosis in Irish older adults in an acute medical assessment unit. ( 29441431 )
2018
12
Role of thrombophilia in splanchnic venous thrombosis in acute pancreatitis. ( 29720864 )
2018
13
Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature. ( 29976241 )
2018
14
Cancer and risk of cerebral venous thrombosis: a case-control study. ( 29125690 )
2018
15
False aneurysm of the popliteal artery complicated by a deep venous thrombosis revealing an exostosis in a 20-year-old young woman. ( 29787853 )
2018
16
Stent implantation for May-Thurner syndrome with acute deep venous thrombosis: acute and long-term results from the ATOMIC (AcTive stenting for May-Thurner Iliac Compression syndrome) registry. ( 29948590 )
2018
17
May-Thurner syndrome and the risk of pulmonary embolism in patients with acute deep venous thrombosis. ( 29909851 )
2018
18
Arterial/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus versus primary and secondary antiphospholipid syndrome: a systematic review and meta-analysis. ( 29879927 )
2018
19
The association between nonselective beta-blockers and portal venous thrombosis in cirrhotic patients: More questions on the horizon. ( 29451177 )
2018
20
Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review. ( 29441008 )
2018
21
Spontaneous occult intracranial hypotension precipitating life-threatening cerebral venous thrombosis: case report. ( 29600909 )
2018
22
Lemierre's syndrome leading to cerebral venous thrombosis. ( 29898085 )
2018
23
Recurrent deep venous thrombosis in a leprosy patient on Sofosbuvir regimen for HCV: a lepra reaction? ( 29974941 )
2018
24
Risk of Venous Thrombosis in Antithrombin Deficiency: A Systematic Review and Bayesian Meta-analysis. ( 29452444 )
2018
25
Recurrent pulmonary embolism associated with deep venous thrombosis diagnosed as protein s deficiency owing to a novel mutation in PROS1: A case report. ( 29742732 )
2018
26
Deep venous thrombosis, pulmonary embolism and long-distance flights. ( 29948593 )
2018
27
Early BBB breakdown and subacute inflammasome activation and pyroptosis as a result of cerebral venous thrombosis. ( 29981290 )
2018
28
Cerebral venous thrombosis as the first presentation of classical homocystinuria in an adult patient. ( 28137899 )
2017
29
Spectrum of Visual Impairment in Cerebral Venous Thrombosis: Importance of Tailoring Therapies Based on Pathophysiology. ( 28904465 )
2017
30
Factors Influencing the Incidence of Papilledema in Patients with Cerebral Venous Thrombosis. ( 29387676 )
2017
31
Cerebral Venous Thrombosis in a Patient with Iron Deficiency Anemia and Thrombocytopenia: A Case Report. ( 29362628 )
2017
32
Is real-time elastography helpful to differentiate acute from subacute deep venous thrombosis? A preliminary study. ( 28940429 )
2017
33
Association of Cerebral Venous Thrombosis and Intracranial Hypotension: Review of 3 Cases. ( 28623115 )
2017
34
Effects of walking in deep venous thrombosis: a new integrated solid and fluid mechanics model. ( 27505011 )
2017
35
Cerebral venous thrombosis: continental disparities. ( 28808795 )
2017
36
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. ( 29282357 )
2017
37
[Cerebral venous thrombosis misinterpreted as migraine]. ( 28330536 )
2017
38
Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer. ( 28246607 )
2017
39
Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study. ( 28618892 )
2017
40
Predictive Factors for Developing Venous Thrombosis during Cisplatin-Based Chemotherapy in Testicular Cancer. ( 28514776 )
2017
41
Major vessel venous thrombosis in patients of posttubercular chronic constrictive pericarditis undergoing pericardectomy: A rare scenario. ( 28701604 )
2017
42
Pyomyositis Complicated by Deep Venous Thrombosis - A Unique Case of Reverse Lemierre's Syndrome. ( 28462553 )
2017
43
Safety and effectiveness of early chemical deep venous thrombosis prophylaxis after spinal cord injury: pilot prospective data. ( 29088948 )
2017
44
Recurrent venous thrombosis related to overweight and obesity: results from the MEGA follow-up study. ( 28439955 )
2017
45
Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. ( 28420787 )
2017
46
Lipid levels and risk of venous thrombosis: results from the MEGA-study. ( 28540474 )
2017
47
Thrombophilia Testing and Venous Thrombosis. ( 29215221 )
2017
48
Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis. ( 28552956 )
2017
49
Aseptic cerebral venous thrombosis associated with a gastric leiomyoma. ( 29560682 )
2017
50
Investigation of Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case-control study. ( 28561456 )
2017